Analyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and Healthways, Inc.

Analysts revised their ratings and price targets on Foamix Pharmaceuticals Ltd (FOMX), Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ), and Healthways, Inc. (HWAY)

Aug 10, 2016 at 3:52 PM
facebook twitter linkedin

Analysts are weighing in on biopharmaceutical stocks Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) and Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), as well as health management stock Healthways, Inc. (NASDAQ:HWAY). Here's a quick roundup of today's brokerage notes on FOMX, JAZZ, and HWAY.

  • FOMX was down more than 7% at its intraday low, after reporting a larger-than-expected per-share loss for the second quarter. However, the stock has since clawed to a 0.5% gain to sit at $8.18, and some analysts expect much more upside for FOMX. Specifically, Guggenheim raised its price target on FOMX to $20 from $10 -- in territory not charted -- and reiterated a "buy" endorsement. Since its most recent low at $5.70 in June, Foamix Pharmaceuticals Ltd shares have added nearly 44%, with pullbacks contained by its 20-day moving average. Short sellers have been keeping a close eye on FOMX, with short interest up 1.5% over the previous two reporting periods, now accounting for 8.8% of FOMX's float -- which would take almost two weeks of trading to cover, at FOMX's average daily volume. 
  • JAZZ is down 6.8% at $139.80 -- set for its worst session in five months -- after an earnings miss and and downwardly revised full-year forecast, though it's just one of several healthcare stocks swimming in red ink today. A handful of analysts have since issued price-target adjustments for JAZZ, including bumps from BMO and Leerink, to $193 and $202, respectively, as well as cuts from Mizuho and Goldman Sachs, to $185 and $195, respectively. Jazz Pharmaceuticals plc – Ordinary Shares is down 22.8% year-over-year, with the shares running into resistance in the $155-$160 region -- home to their 80-week moving average -- since April. Nevertheless, analysts are still upbeat on the stock, with all 11 brokerage firms weighing in calling JAZZ a "strong buy."
  • HWAY is up 18.8% at $21.45 -- and just off a new annual high of $22.76 -- after the company reported an earnings beat and announced that Robert E. Dries will take over the position of chief financial officer. Additionally, HWAY received price-target raises from Piper Jaffray (to $25.50), UBS (to $19), and Barrington (to $29). Thanks to today's pop, the stock is now up 67% year-to-date, and there's likely some bearish traders kicking rocks. Short interest on Healthways, Inc. jumped 5.2% in the latest reporting period, and now accounts for 9.3% of the stock's available float 
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!